Pharmacokinetic Interaction between Antiretroviral and Cytotoxic therapy in HIV-infected patients - a pilot study

Pharmacokinetic Interaction between Antiretroviral and Cytotoxic therapy in HIV-infected patients - a pilot study - Phineac-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37346

Enrollment

Registered

2012-03-26

Start date

2013-03-25

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus (HIV) lymphoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Biopsy proven lymphoma Treated with cyclophosphamide, doxorubicin, vinblastine and/or vincristine proven HIV positive on HAART

Exclusion criteria

Exclusion criteria: Seriously compromised peripheral venous vasculature complicating venous blood sampling No written informed consent obtained

Design outcomes

Primary

Measure	Time frame
Serum levels of the antineoplastic and antiretroviral agents will be measured. Pharmacokinetic parameters will be calculated and compared to individual and population parameters. Clinical parameters, adverse events and if possible clinical outcome will be collected by laboratory values and EORTC-QLQ C30 questionnaires and related to the collected pharmacokinetic parameters.	—

Countries

Netherlands

Outcome results